Abstract
Nitric oxide (NO) is an endogenous compound, which plays a fundamental role in the modulation of the function of the cardiovascular system, where it induces vasorelaxing and antiplatelet responses, mainly through the stimulation of guanylate cyclase and the increase of cGMP. Many drugs of common, timehonoured clinical use (for example, glycerol trinitrate and all the vasodilator nitrites and nitrates) act via the release of exogenous NO, thus mimicking the effects of the endogenous factor. In the last few years, a revision of the "one-compound-one-target" paradigm has led pharmacologists and pharmaceutical chemists to develop new classes of molecules which combine different pharmacodynamic properties. This innovative pharmacological/pharmaceutical strategy has produced hybrid drugs, with a dual mechanism of action: a) the slow release of nitric oxide and b) another fundamental pharmacodynamic profile. These drugs have been obtained by inserting appropriate NO-donor chemical groups (i.e. nitrate esters, nitrosothiols, etc.), linked to a known drug, by means of a variable spacer moiety. These new pharmacodynamic hybrids present the advantage of combining a basic mechanism of action (for example, cyclooxygenase inhibition, beta-antagonism or ACE inhibition) with a slow release of NO, which may be useful either to reduce adverse side effects (for example, the gastrotoxicity of NSAIDs), or to improve the effectiveness of the drug (for example, conferring direct vasorelaxing and antiplatelet effects on an ACEinhibitor). The aim of this review is to present the chemical features of NO-releasing hybrids of cardiovascular drugs, and to explain the pharmacological improvements obtained by the addition of the NO-donor properties.
Keywords: Nitric oxide, NO-donor, hybrid drugs, cardiovascular drugs
Current Medicinal Chemistry
Title: NO-Releasing Hybrids of Cardiovascular Drugs
Volume: 13 Issue: 6
Author(s): A. Martelli, S. Rapposelli and V. Calderone
Affiliation:
Keywords: Nitric oxide, NO-donor, hybrid drugs, cardiovascular drugs
Abstract: Nitric oxide (NO) is an endogenous compound, which plays a fundamental role in the modulation of the function of the cardiovascular system, where it induces vasorelaxing and antiplatelet responses, mainly through the stimulation of guanylate cyclase and the increase of cGMP. Many drugs of common, timehonoured clinical use (for example, glycerol trinitrate and all the vasodilator nitrites and nitrates) act via the release of exogenous NO, thus mimicking the effects of the endogenous factor. In the last few years, a revision of the "one-compound-one-target" paradigm has led pharmacologists and pharmaceutical chemists to develop new classes of molecules which combine different pharmacodynamic properties. This innovative pharmacological/pharmaceutical strategy has produced hybrid drugs, with a dual mechanism of action: a) the slow release of nitric oxide and b) another fundamental pharmacodynamic profile. These drugs have been obtained by inserting appropriate NO-donor chemical groups (i.e. nitrate esters, nitrosothiols, etc.), linked to a known drug, by means of a variable spacer moiety. These new pharmacodynamic hybrids present the advantage of combining a basic mechanism of action (for example, cyclooxygenase inhibition, beta-antagonism or ACE inhibition) with a slow release of NO, which may be useful either to reduce adverse side effects (for example, the gastrotoxicity of NSAIDs), or to improve the effectiveness of the drug (for example, conferring direct vasorelaxing and antiplatelet effects on an ACEinhibitor). The aim of this review is to present the chemical features of NO-releasing hybrids of cardiovascular drugs, and to explain the pharmacological improvements obtained by the addition of the NO-donor properties.
Export Options
About this article
Cite this article as:
Martelli A., Rapposelli S. and Calderone V., NO-Releasing Hybrids of Cardiovascular Drugs, Current Medicinal Chemistry 2006; 13 (6) . https://dx.doi.org/10.2174/092986706776055634
DOI https://dx.doi.org/10.2174/092986706776055634 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytotherapeutic Agents for Benign Prostatic Hyperplasia: An Overview
Mini-Reviews in Medicinal Chemistry EDITORIAL (Natural Products for Treatment of Alzheimer's Disease and Related Diseases: Understanding their Mechanism of Action)
Current Neuropharmacology Curcumin is an Inhibitor of p300 Histone Acetylatransferase
Medicinal Chemistry Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Novel Diagnostics R&D for Public Health and Personalized Medicine in Taiwan: Current State, Challenges and Opportunities
Current Pharmacogenomics and Personalized Medicine Editorial: The Biologic Era: A Comprehensive Approach for Inflammatory and Immune-mediated Diseases
Current Pharmaceutical Biotechnology Editorial [Hot Topic: B Lymphocytes as Programmers and Effectors of Immunity, their Roles Beyond Antibody Production (Guest Editor: Simon Fillatreau)]
Infectious Disorders - Drug Targets Tofacitinib-induced Ramsay- Hunt Syndrome in a Patient with Rheumatoid Arthritis
Current Drug Safety Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Ovulation, Implantation and Placentation in Females with Obesity and Metabolic Disorders: Life in the Balance
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparison of HCV Core and CoreE1E2 Virus-Like Particles Generated by Stably Transfected Leishmania tarentolae for the Stimulation of Th1 Immune Responses in Mice
Current Drug Delivery Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects
Current Pharmaceutical Design Bone Marrow Niches for Hematopoietic Stem Cells and Immune Cells
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The beneficial effect of Cape gooseberry juice on carbon tetrachloride-induced neuronal damage
CNS & Neurological Disorders - Drug Targets Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews